venetoclax resistance

IDH3 as a Metabolic Checkpoint Modulating Venetoclax Resistance in AML Stem Cells

By MedXY 09/27/2026

This article elucidates how the TCA cycle enzyme IDH3 critically regulates metabolic fitness in AML stem cells, influencing venetoclax resistance and offering a novel target to improve therapeutic outcomes.

Hematology-Oncology news

Targeting PRMT9 to Overcome Venetoclax Resistance in AML: A Paradigm Shift in Therapeutic Strategy

By MedXY 09/13/2026

PRMT9-mediated arginine methylation drives venetoclax resistance in AML by altering RNA splicing and protein synthesis. Targeting PRMT9 restores venetoclax sensitivity, offering a promising approach to combat resistant AML.

Clinical Updates Hematology-Oncology news

G3BP2-Mediated Venetoclax Resistance via ELF1-Driven MCL1 Transcription in Acute Myeloid Leukemia: Mechanisms and Therapeutic Implications

By MedXY 07/24/2026

This review synthesizes evidence on the role of RNA-binding protein G3BP2 in conferring venetoclax resistance in AML through stabilizing ELF1 mRNA and upregulating MCL1 transcription, highlighting novel therapeutic avenues combining G3BP2 inhibition with venetoclax.